Form 4: InMed Pharmaceuticals Executive Granted Stock Options

InMed Pharmaceuticals' Senior VP & General Manager, Shane Aaron Johnson, was granted 1,500 stock options on December 20, 2024.

Summary

• Shane Aaron Johnson, Senior VP & General Manager at InMed Pharmaceuticals, was granted 1,500 employee stock options on December 20, 2024.
• These options have an exercise price of $4.14 and will vest monthly over 36 months, starting from the grant date.
• The options expire on December 19, 2029.
• Following this transaction, Mr. Johnson directly owns 3,900 derivative securities.
• The number of shares reflects a 1-for-20 reverse stock split that occurred on November 14, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management interests with shareholders. There are no negative implications.

Positives

• The granting of stock options to a key executive aligns their interests with the company's performance and shareholder value.
• The vesting schedule of 36 months encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of 36 months is typical for such grants, aligning executive interests with long-term company performance.
• The exercise price of $4.14 is specific to InMed's stock and market conditions at the time of the grant.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning executive interests with company performance.
• The vesting schedule encourages long-term commitment from the executive, which can benefit the company and its stakeholders.

Key Dates

Keywords

stock options, executive compensation, insider trading, InMed Pharmaceuticals, Shane Aaron Johnson, derivative securities, reverse stock split